Welcome to our dedicated page for 180 Life Sciences Warrant news (Ticker: ATNFW), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences Warrant stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 180 Life Sciences Warrant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 180 Life Sciences Warrant's position in the market.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of a private placement of 2,564,000 shares and warrants, raising approximately $11.7 million. The shares are priced at $4.55 each, with warrants exercisable at $5.00. Proceeds will support corporate purposes, working capital, and drug development programs.
Maxim Group LLC was the sole placement agent for this transaction. The securities offered were only available to accredited investors and remain unregistered under the Securities Act of 1933.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $11.7 million by issuing 2,564,000 shares of common stock at a price of $4.55 each, along with warrants. The exercise price for the warrants is $5.00, and they will expire in five years. Closing is expected on February 23, 2021. The offering targets accredited investors and includes a commitment to file registration statements with the SEC for resale of the shares and warrants.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference, with on-demand presentations available between January 11-14, 2021. The clinical-stage biotechnology company focuses on developing novel drugs for inflammatory diseases, fibrosis, and pain, currently leading Phase 2b/3 trials targeting anti-TNF therapies. The presentation will be accessible via the company's website for up to 90 days post-conference.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the LD Micro Virtual Main Event 2020 Conference on December 15, 2020, featuring CEO Dr. James Woody's presentation at 1:40 PM EST. The company focuses on developing drugs for inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials. Their unique format includes 10 minutes of presentation followed by a 10-minute Q&A session. For registration, visit the specified link.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its Nasdaq opening bell ceremony on November 27, 2020, celebrating its recent IPO. CEO Dr. James Woody and the team will participate virtually, emphasizing the company's focus on developing novel drugs for inflammatory diseases, fibrosis, and pain. The lead program is in Phase 2b/3 trials, leveraging expertise from renowned institutions. This milestone marks the company's transition to public status, showcasing its commitment to addressing unmet medical needs.
180 Life Sciences Corp. (NASDAQ: ATNF) has expanded its intellectual property (IP) portfolio, focusing on treatments for inflammatory diseases, fibrosis, and pain. The company now holds 16 patent families with 42 issued patents and 32 pending applications across key markets such as the U.S., Canada, Europe, and China. Recent developments include a notice from the USPTO about a new patent application for a method treating frozen shoulder and the acceptance of a patent for early-stage Dupuytren's Disease. Additional patents have been granted in the EU, enhancing its market presence.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a successful merger with KBLM Merger Corp IV, marking its transition to a stand-alone public entity. CEO Dr. James Woody aims to leverage the expertise of a seasoned management team to advance the company's drug pipeline, focusing on unmet medical needs in inflammatory diseases, fibrosis, and pain. Key programs include a Phase 2b/3 trial for Dupuytren's contracture and pre-clinical efforts on synthetic cannabidiol analogs. The company intends to maintain low operating expenses through grant funding.
180 Life Sciences Corp. (NASDAQ: ATNF) has announced the successful closing of its merger with KBL Merger Corp IV, officially becoming a publicly traded company on Nasdaq. The company focuses on developing novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain. With a robust pipeline, its lead program in Phase 2b/3 targets Dupuytren's contracture, affecting over 15 million Americans. The leadership team includes notable experts such as Dr. James Woody and Prof. Sir Marc Feldmann, with expectations for significant advancements in therapeutic solutions.
FAQ
What is the current stock price of 180 Life Sciences Warrant (ATNFW)?
